NCT04342962终止2 期
Tagraxofusp in Patients With CD123+ or With Blastic Plasmacytoid Dendritic Cell Neoplasm Immunophenotype-like Acute Myeloid Leukemia
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 25
- 试验地点
- 10
- 主要终点
- The objective response rate (ORR)
研究概览
简要总结
Non-randomized, open-label, multicenter phase II Study for the treatment of
- 25 R/R BPDCN-IF (CD123/CD4/CD56 positive) AML patients and
- 25 patients presenting R/R AML CD123+, but negative for either, or both, CD4 and CD56.
Patients will be treated with 12 mcg/kg/day of tagraxofusp for 5 days, for at least 4 cicles.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patient has evidence of AML in the peripheral blood and/or bone marrow with either BPDCN-IF [CD123/CD4/CD56 (+)] or with AML that is CD123+ but negative for either, or both, CD4 and CD
- •The patient is ≥18 years old.
- •The patient must be refractory to at least one previous line of conventional therapy (either high dose therapy or hypomethylating agents) or relapsed after receiving conventional therapy (a maximum of two previous line of therapy is admitted).
- •The patient has an Eastern Cooperative Oncology Group (ECOG) performance score (PS) of 0 to
- •The patient has adequate baseline organ function, including cardiac, renal, and hepatic function:
- •Left ventricular ejection fraction (LVEF) ≥institutional lower limit of normal as measured by multigated acquisition (MUGA) scan or 2-dimensional (2-D) echocardiography(ECHO) within 21 days before start of therapy and no clinically significant abnormalities on a 12-lead electrocardiogram (ECG).
- •Serum creatinine ≤1.5 mg/dL (133 μmol/L).
- •Serum albumin ≥3.2 g/dL (32 g/L) (albumin infusions are not permitted to enable eligibility).
- •Bilirubin ≤1.5 mg/dL (26 μmol/L).
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 times the upper limit of normal (ULN).
- •If the patient is a woman of childbearing potential (WOCBP), she must have a negative serum or urine pregnancy test at screeningwithin 1 week before treatment.
- •The patient has signed informed consent before initiation of any study-specific procedures or treatment.
- •The patient is able to adhere to the study visit schedule and other protocol requirements, including follow-up for survival assessment.
- •The patient (male and female) agrees to use acceptable contraceptive methods for the duration of time on the study and continue to use acceptable contraceptive methods for 1 week after the last infusion of tagraxofusp.
排除标准
- •The patient has a diagnosis of acute promyelocytic leukemia (APL; FAB subtype M3).
- •The patient has persistent clinically significant toxicities of Grade≥2 from previous chemotherapy (excluding alopecia, nausea, fatigue, and liver function tests [as mandated in the inclusion criteria]).
- •The patient has received treatment with chemotherapy, wide-field radiation, or biologic therapy within 14 days of study entry.
- •The patient has received treatment with an investigational agent within 14 days of study entry.
- •The patient has previously received treatment with tagraxofusp.
- •The patient has an active malignancy and/or cancer history (excluding antecedent MDS) that may confound the assessment of the study endpoints. Patients with a past cancer history (within 2 years of entry) with substantial potential for recurrence and/or ongoing active malignancy will be evaluated on a case by case basis. Patients with the following neoplastic diagnoses are eligible: non-melanoma skin cancer, carcinoma in situ, cervical intraepithelial neoplasia, organ-confined prostate cancer with no evidence of progressive disease.
- •The patient has clinically significant cardiovascular disease (eg, uncontrolled or any New York Heart Association Class 3 or 4 congestive heart failure, uncontrolled angina, history of myocardial infarction, unstable angina or stroke within 6 months before study entry, uncontrolled hypertension or clinically significant arrhythmias not controlled by medication).
- •The patient has uncontrolled, clinically significant pulmonary disease (eg, chronic obstructive pulmonary disease, pulmonary hypertension) that, in the opinion of the Investigator, would put the patient at significant risk for pulmonary complications during the study.
- •The patient has known active or suspected central nervous system (CNS) leukemia. If suspected, CNS leukemia should be ruled out with relevant imaging and/or examination of cerebrospinal fluid.
- •The patient is receiving immunosuppressive therapy - with the exception of low-dose prednisone (≤10 mg/day) - for treatment or prophylaxis of graft-versus-host disease (GVHD). If the patient has been on immunosuppressive treatment or prophylaxis for GVHD, the treatment(s) must have been discontinued at least 14 days before study treatment and there must be no evidence of Grade ≥2 GVHD.
- •The patient has uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, disseminated intravascular coagulation, or psychiatric illness/social situations that would limit compliance with study requirements.
- •The patient is pregnant or breastfeeding.
- •The patient has known positive status for human immunodeficiency virus or active or chronic hepatitis B or hepatitis C (Patients with positive serology for HBV can be enrolled and must receive antiviral prophylaxis - i.e lamivudine or entcavir).
- •The patient is oxygen-dependent.
- •The patient has any medical condition that, in the opinion of the Investigator, places the patient at an unacceptably high risk for toxicities.
- •The patient has AML and requires more than 1 g/day of hydroxyurea (Hydroxyureaispermittedatdoses of ≤1 g/day.)
研究组 & 干预措施
Experimental arm
Experimental
12 mcg/kg/day of tagraxofusp for 5 days, for at least 4 cycles of therapy; each cycle is 21 days.
Patients will receive the study drug until disease progression or in case of toxicity.
干预措施: tagraxofusp (Drug)
结局指标
主要结局
The objective response rate (ORR)
时间窗: 4 months
Evaluate the activity of tagraxofusp, in terms of ORR (PR + CR + CRi), in patients with CD123+ or BlasticPlasmacytoid Dendritic Cell Neoplasm-like phenotype (BPDCN-IF) Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML).
次要结局
- Overall survival (OS)(24 months)
- Rate of AEs and SAEs(28 months)
- Event Free Survival (EFS)(24 months)
- Cumulative incidence of relapse (CIR)(24 months from response assessment)
- Percentage of patients undergoing allogeneic stem cell transplantation(12 months)
- Disease Free Survival (DFS)(24 months from response assessment)
研究者
研究点 (10)
Loading locations...
相似试验
进行中（未招募）
1 期
Study aimed at evaluating the efficacy of Tagraxofusp, as a possible targeted therapy, in patients with Acute Myeloid Leukemia, for whom previous chemotherapy treatments have proved to be ineffective.EUCTR2020-001543-94-ITFONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS50
招募中
1 期
Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell TransplantAcute Myeloid LeukemiaMyelodysplastic SyndromeNCT06498973City of Hope Medical Center43
终止
2 期
Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell TransplantBlastic Plasmacytoid Dendritic Cell NeoplasmNCT04317781M.D. Anderson Cancer Center3
进行中（未招募）
1 期
Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelofibrosisNCT05233618Karen Ballen, MD44
招募中
1 期
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic MalignanciesHematologic MalignancyALLBPDCNMDSLymphoblastic LymphomaLymphoma, B-CellLymphoma, T-CellMixed Phenotype Acute LeukemiaAMLHodgkin LymphomaAcute Undifferentiated LeukemiaNCT05476770Therapeutic Advances in Childhood Leukemia Consortium54